Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N J Korman

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Dermatologic Clinics|January 8, 2000
New and emerging therapies in the treatment of blistering diseasesN J Korman
The Journal of Investigative Dermatology|December 1, 1995
In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigenN J Korman
The British Journal of Dermatology|June 22, 2019
Management of psoriasis as a systemic disease: what is the evidence?N J Korman
Dermatologic Clinics|October 1, 1990
PemphigusN J Korman
Dermatologic Clinics|November 14, 2001
New immunomodulating drugs in autoimmune blistering diseasesN J Korman
Dermatologic Clinics|July 1, 1993
Bullous pemphigoidN J Korman
Archives of Dermatology|October 8, 1998
Bullous pemphigoid. The latest in diagnosis, prognosis, and therapyN J Korman
The British Journal of Dermatology|December 1, 1995
Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoidN J Korman, S G Woods
Archives of Dermatology|October 1, 1996
Immune-mediated subepithelial blistering diseases of the mucous membranes. Improving the detection of circulating autoantibodies by the use of concentrated serum samplesN J Korman, R D Watson
Journal of the American Academy of Dermatology|September 27, 2000
Cicatricial pemphigoidT E Fleming, N J Korman
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Dermatologic Clinics|January 8, 2000
New and emerging therapies in the treatment of blistering diseasesN J Korman
The Journal of Investigative Dermatology|December 1, 1995
In situ-bound antibodies eluted from the skin of patients with bullous pemphigoid are preferentially directed against the 230-kD bullous pemphigoid antigenN J Korman
The British Journal of Dermatology|June 22, 2019
Management of psoriasis as a systemic disease: what is the evidence?N J Korman
Dermatologic Clinics|October 1, 1990
PemphigusN J Korman
Dermatologic Clinics|November 14, 2001
New immunomodulating drugs in autoimmune blistering diseasesN J Korman
Dermatologic Clinics|July 1, 1993
Bullous pemphigoidN J Korman
Archives of Dermatology|October 8, 1998
Bullous pemphigoid. The latest in diagnosis, prognosis, and therapyN J Korman
The British Journal of Dermatology|December 1, 1995
Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoidN J Korman, S G Woods
Archives of Dermatology|October 1, 1996
Immune-mediated subepithelial blistering diseases of the mucous membranes. Improving the detection of circulating autoantibodies by the use of concentrated serum samplesN J Korman, R D Watson
Journal of the American Academy of Dermatology|September 27, 2000
Cicatricial pemphigoidT E Fleming, N J Korman
Pageof 5